Senate committee approves pharmacy chapter rewrite but strips two compounding labeling subsections

The Senate Health and Welfare Committee approved pending rule chapter IDAPA 24.36.01 (docket 24-3601-2402) from the Idaho State Board of Pharmacy on a motion that struck subsections identified as 214 E(i) and 214 E(ii).

The pending rule package, presented by Nikki Chopsky, bureau chief of health professions at the Division of Occupational and Professional Licenses and executive officer for the Idaho State Board of Pharmacy, consolidated and reorganized more than 35 rule changes across definitions, licensure, practice standards, discipline, fees, compounding, sterile preparations and prescription drug monitoring. "Following the passage of house bill 527 ... the board reviewed and adopted this temporary rule docket in March of 2024," Chopsky said during her presentation.

Committee members said the compounding and labeling language raised particular concern because the federal Food and Drug Administration had issued draft guidance but not a final rule. Senator Lenny argued the state should avoid imposing a rule that might reduce access or raise costs while federal guidance remains unsettled. "It seems like Idaho is the teacher saying, I know the principal said we can have snacks on campus, but we're gonna enforce this no snack rule," Lenny said, using an analogy to describe potential access consequences.

The board had sought to keep a labeling provision for distribution of compounded products (identified in the materials as old rule 40605 / new rule 214 subsection e). Chopsky told the committee that the board retained language that mirrors federal labeling requirements and had discussed stakeholder concerns; she said the board was open to further work with stakeholders and noted federal guidance remains draft and nonbinding. "The board stands committed to working transparently with these stakeholders and others for a workable solution in an environment that is unsettled at this time," Chopsky said.

After discussion, Senator Lenny offered a substitute motion to approve the pending docket while striking the two disputed subsections (214 E(i) and 214 E(ii)). The committee adopted that substitute on a roll-call tally the chair summarized as 7 yes and 2 no. The committee had earlier taken no action on the related temporary-rule docket (24-3601-2401), a separate motion (moved by Senator Harris, seconded by Senator Wintrow) that passed by voice vote so the temporary rules would expire.

The approved pending chapter keeps a number of substantive changes intended to reduce duplication with statute, including combining definition sections, moving certain prescriber-performance provisions into statute (cited by Chopsky as Title 54, Chapter 17), moving fee language into a fee table and capping fees at current legislatively approved rates, changing annual inventory to biannual inventory, tightening reporting timeframes for controlled-substance reporting to end of business day, and removing outdated or duplicative text identified through the division's zero‑based regulation (ZBR) review. Chopsky told the committee the board had engaged stakeholders in multiple public meetings and hearings and that participation often included "maybe 12 to 15 people in the room and maybe as many as 20 online."

The committee's action leaves the Board of Pharmacy and affected stakeholders to continue discussions about labeling and distribution pathways for compounded products; the board indicated it would work further with stakeholders and could revisit the questions if federal guidance changes.

Votes at a glance: the committee took no action on temporary docket 24-3601-2401 (motion by Senator Harris; passed by voice), and approved pending docket 24-3601-2402 with the exception of subsections 214 E(i) and 214 E(ii) (substitute motion by Senator Lenny; roll-call summarized by the chair as 7 yes, 2 no).

The committee moved on to other rule dockets after the pharmacy items.